Combined administration of interleukin-2 and 18 with anti-PD-L1 antibody induces CCL5-positive CD8 T cells to suppress liver tumors
Masamichi Kimura, Kenzaburo Yamaji, Kenichi Harada, Hideya Kawaji, Jun Imamura, Haruki Okamura, Yoshimasa Tanaka, Michinori Kohara, Kiminori Kimura, Christof Niehrs · 2026
Read Combined administration of interleukin-2 and 18 with anti-PD-L1 antibody induces CCL5-positive CD8 T cells to suppress liver tumors by Masamichi Kimura, Kenzaburo Yamaji, Kenichi Harada, Hideya Kawaji, Jun Imamura, Haruki Okamura, Yoshimasa Tanaka, Michinori Kohara, Kiminori Kimura, Christof Niehrs (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13096734.txt.
Description
Remarkable progress has been made in cancer immunotherapy, partly because of the development of immune checkpoint inhibitors. However, their efficacy varies across cancer types, with limited response observed in solid tumors, such as hepatocellular carcinoma (HCC). The primary cause of this low efficacy is insufficient infiltration of effector cells, such as cytotoxic CD8+ T cells, into the tumor tissue.
Catalog record
| CREATOR | Masamichi Kimura, Kenzaburo Yamaji, Kenichi Harada, Hideya Kawaji, Jun Imamura, Haruki Okamura, Yoshimasa Tanaka, Michinori Kohara, Kiminori Kimura, Christof Niehrs |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |